Table 3.
Health‐related outcome estimates among matched cohort members
| Outcome | Adherence | Echocardiogram | RAS inhibitors | Beta‐blockers | MRAs | ||||
|---|---|---|---|---|---|---|---|---|---|
| RMST (months) | HR (95% CI) | RMST (months) | HR (95% CI) | RMST (months) | HR (95% CI) | RMST (months) | HR (95% CI) | ||
| Composite outcome a | No adherent | 36.9 | 1.00 (Ref.) | 35.7 | 1.00 (Ref.) | 35.2 | 1.00 (Ref.) | 34.8 | 1.00 (Ref.) |
| Adherent | 38.5 | 0.91 (0.86–0.98) | 37.6 | 0.89 (0.86–0.93) | 36.8 | 0.92 (0.89–0.95) | 35.4 | 0.96 (0.92–1.01) | |
| All‐cause death | No adherent | 44.9 | 1.00 (Ref.) | 42.9 | 1.00 (Ref.) | 42.3 | 1.00 (Ref.) | 42.3 | 1.00 (Ref.) |
| Adherent | 46.5 | 0.88 (0.83–0.93) | 45.3 | 0.84 (0.80–0.88) | 44.3 | 0.89 (0.85–0.93) | 42.1 | 1.01 (0.96–1.07) | |
CI, confidence interval; HR, hazard ratio; MRAs: mineralocorticoid receptor antagonists; RAS, renin–angiotensin system; RMST, restricted mean survival time.
a
Cardiovascular hospitalization or all‐cause death.